EDAP to Attend 33rd Annual Piper Sandler Virtual Healthcare Conference

LYON, France, November 29, 2021 – EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will participate in a corner conversation fire and will host the investor 1×1 meetings at the 33rd Annual Piper Sandler Virtual Healthcare Conference, which runs from November 29 to December 2.

EDAP will participate in investor meetings on Tuesday 30 November.

A video replay of the fireside chat will be available in the Investors section of the EDAP website after the event concludes.


A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes minimally invasive medical devices for various pathologies using ultrasound technology worldwide. By combining the latest technologies in imaging and treatment modalities in its complete line of robotic HIFU devices, EDAP TMS has introduced the Focal One® in Europe and the United States as the answer to all the requirements for an ideal ablation of the prostate tissue. With the addition of the ExactVu ™ micro-ultrasound machine, EDAP TMS is now the only company to offer a complete solution from diagnosis to focal treatment of prostate cancer. EDAP TMS also manufactures and distributes other medical equipment, including the Sonolith® i-move lithotripter and lasers for the treatment of urinary stones using extracorporeal shock wave lithotripsy (ESWL). For more information about the Company, please visit http://www.edap-tms.com, and us.hifu-prostate.com.

Forward-looking statements

In addition to historical information, this press release contains forward-looking statements. These statements are based on the current expectations of management and are subject to a number of risks and uncertainties, including matters which we do not yet know or do not currently consider to be material, and there can be no assurance that planned events will occur or that the set goals will actually be achieved. Important factors that could cause actual results to differ materially from results anticipated in forward-looking statements include, among others, the clinical condition and market acceptance of our HIFU devices and the continued commercial potential of our device. lithotripsy, as well as the duration and severity of the recent COVID-19 outbreak, including its impacts across all of our businesses on demand for our devices and services. Factors that could cause such a difference may also include, but are not limited to, those described in documents filed by the Company with the Securities and Exchange Commission and in particular, in the “Caution Regarding Forward-Looking Information” sections. and “Risk Factors” in the Company’s Annual Report on Form 20-F.

Company contact
Blandine Comfort
Investor Relations / Legal Affairs
+33 4 72 15 31 50
[email protected]

Investor contact
Jean Fraunces
LifeSci Advisors, LLC
[email protected]

Previous Ethereum Price has just made a comeback. After that ?
Next Jack Dorsey steps down as CEO of Twitter